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Abstract
Soluble Antigen Arrays (SAgAs) were developed for treating mice with experimental autoimmune 
encephalomyelitis (EAE), a mouse model of multiple sclerosis. SAgAs are composed of 
hyaluronan with grafted EAE antigen and LABL peptide (a ligand of ICAM-1). SAgA dose was 
tested by varying injection volume, SAgA concentration, and administration schedule. Routes of 
administration were explored to determine the efficacy of SAgAs when injected intramuscularly, 
subcutaneously, intraperitoneally, intravenously, or instilled into lungs. Injections proximal to the 
central nervous system (CNS) were compared to distal injection sites. Intravenous dosing was 
included to determine if SAgA efficiency results from systemic exposure. Pulmonary instillation 
was included since reports suggest T cells are licensed in the lungs before moving onto the 
CNS1,2. Decreasing the volume of injection or SAgA dose reduced treatment efficacy. Treating 
mice with a single injection on day 4, 7, or 10 also reduced efficacy compared to injecting on all 
three days. Surprisingly, changing the injection site did not lead to a significant difference in 
efficacy. Intravenous administration showed efficacy similar to other routes, suggesting SAgAs 
act systemically. When SAgAs were delivered via pulmonary instillation, however, EAE mice 
failed to develop any symptoms, suggesting a unique lung mechanism to ameliorate EAE in mice.
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Multiple sclerosis (MS), an autoimmune disease that destroys the myelin sheath, impacts the 
patient both physically and mentally3. Loss of vision, varying degrees of paralysis, loss of 
balance, and lack of coordination constitute the most common physical symptoms. Mental 
symptoms include slurring of speech and cognitive difficulties. The onset of disease 
typically occurs in young adults, but the disease continues into adulthood. Current 
therapeutic interventions can mitigate symptoms but none address the underlying immune 
response specific to offending myelin autoantigens.
MS can be classified into the following types: (1) secondary progressive, (2) primary 
progressive, (3) progressive relapsing, and (4) relapsing remitting. Because relapsing 
remitting MS (RRMS) affects 80% of patients with MS, current treatments have focused on 
this form of the disease4. In RRMS, the symptoms manifest periodically. In a period of 
relapse, the patient is acutely aware of the symptoms, but feels them to a lesser degree 
during periods of remission. Over time, symptoms are continually perceived even during 
periods of remission, a development indicative of progressive RRMS.
Not much is known about the cause of MS in humans. One theory asserts that MS is a 
systemic disease in its early stages, and in the later stages MS is localized to the lymph 
nodes located close to the spinal cord{Weller, 2010 #21}5. As a result, designing a treatment 
that can be active at the lymph nodes may be important. Another theory suggests that T cells 
are licensed (programmed with a tropism for the cervical lymph nodes) in the lungs before 
being sent to the CNS, alluding that an important site of intervention may be in the lungs, 
instead of the cervical lymph nodes1,6.
The animal model typically used to mimic MS is EAE, where young mice are given 
adjuvant along with specific epitopes of PLP (proteolipid protein) or other antigens from 
proteins that make up myelin sheath7–9. In this PLP-induced EAE model, one cycle of MS-
like symptoms is followed by remission over a 25-day period. Clinical scores are assigned 
by the degree of paralysis and balance. Other symptoms usually present in MS, such as 
cognitive ability, are difficult to measure in mice. The severity of EAE is measured by the 
clinical scores given to each mouse, with an increase in score indicating an increasing 
degree of paralysis, ascending from the tail to the hind-limbs and then the fore-limbs as the 
disease worsens.
The available treatments for MS are known to slow the disease progression and to manage 
specific symptoms. In early stages of the illness, disease-modifying treatments like 
interferon-β, glatiramer acetate, mitoxantrone, and natalizumab are prescribed. Natalizumab, 
also known as Tysabri®, inhibits transit of lymphocytes across the blood-brain barrier. In the 
later stages of the disease, very low dose cancer chemotherapeutics may be used to suppress 
the immune system while minimizing systemic toxicity10. Another approved treatment, 
fingolimod (Gilenya®), sequesters lymphocytes within lymph nodes, thereby restricting 
further destruction of the myelin sheath11. This leaves the patient open to opportunistic 
infections, however, as is the case with global immunosuppressors. Designing therapies that 
specifically target lymphocytes associated with MS or that induce tolerance to autoantigens 
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by inhibiting costimulation during autoantigen recognition may further stymie the 
progression of the disease.
Our lab has developed Soluble Antigen Arrays (SAgAs), composed of a hyaluronic acid 
(HA) backbone with grafted autoantigen (e.g. PLP epitope) and a second peptide, such as an 
ICAM-1 ligand (LABL) (Table 1)12. The size of SAgAs can be designed to drain with 
interstitial fluid and fit through the pores of lymphatic vessels, which range between 10 nm 
and 100 nm13. At least three factors affect SAgA drainage and, ultimately, absorption: the 
site of injection, diffusion of the SAgA, and local vascular and lymphatic network. After 
subcutaneous injection, for example, HA can drain to lymph nodes and certain molecular 
weights of HA can have a long retention time14. By varying the route of administration (site 
of injection and the type of injection), we investigated which route offers the best efficacy. 
SAgA treatment alleviates the clinical symptoms of EAE, yet the mechanism of action is 
still unclear12. Here, variations in dose schedule, SAgA dose, injection volume, and 
different routes of administration were tested to improve understanding of the clinical 
mechanism. Intramuscular (IM), subcutaneous (SC), intraperitoneal (IP), intravenous (IV), 
and pulmonary instillation (PI) routes of administration were studied.
MATERIALS AND METHODS
Peptide Synthesis
Peptides were made using an automated solid phase peptide synthesizer (Pioneer; Perceptive 
Biosystems, Framingham, MA). 9-florenylmethyloxycarbonyl-protected amino acids were 
used to synthesize both PLP139-151 and LABL. In order to conjugate these peptides onto 
HA, an aminooxy (Ao) group was added to the N-terminus of PLP and LABL in the peptide 
synthesizer. Peptides were cleaved off of the resin using trifluoroacetic acid (TFA) and 
scavengers.
The peptides were then purified using a C18 semipreparative column (Higgins Analytical, 
Proto200, 5 μm, 200 Å, 250x20mm) with reversed-phase high performance liquid 
chromatography (HPLC). A gradient method was used to purify the peptides, with an 
aqueous mobile phase A (94.9% d.d. H2O, 5% acetonitrile, and 0.1% TFA) and an organic 
mobile phase B (99.9% acetonitrile and 0.1% TFA). The purity of the peptides was analyzed 
using HPLC on a C18 analytical column (Higgins Analytical, Proto200, 5 μm, 200 Å, 
250x4.6mm) with the same mobile phases and similar gradient program. The molecular 
weight of the peptides was identified using an electrospray ionization time-of-flight mass 
spectrometer (Supplemental Figure 1).
SAgA Synthesis
After the peptides were purified, they were then conjugated onto HA. A 2-mg/mL solution 
of HA (16.9 kDa, 16 kDa, Lifecore Biomedical, Chaska, MN) was made using 20 mM 
acetate buffer at pH 5.5. AoLABL and AoPLP were mixed together in equal molar 
proportions, then added to the 2-mg/mL HA solution at a ratio of 1 aminooxy-peptide to 2 
monomers of HA. The reaction continued for 24 hours, and then the reaction was dialyzed 
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(MW 3500, 6000–8000) against purified water for 24 hours. Samples were frozen and dried 
using a lyophilizer.
SAgAs were further analyzed to check peptide content. The SAgAs were dissolved in 0.1-N 
HCl at pH 1 for at least 4 hours to cleave the peptides. Using a calibration curve of free 
AoLABL and AoPLP at various concentrations, the amount of peptides in SAgAs were 
determined via reversed-phase HPLC on a C18 analytical column.
Dynamic Light Scattering (DLS)
The size distribution of SAgAs were determined using a Brookhaven Zeta-PALS at various 
concentrations (0.5 – 10 mg/mL) in PBS after they were filtered through a 0.45 μm PVDF 
membrane. Light scattering was detected at 90° and using a laser operated at 658 nm. The 
hydrodynamic radius (Rh) was determined from the Stokes-Einstein equation: 
Rh=kbT/6πηDT, where kb is the Boltzmann’s constant, T is temperature (K), η is the solvent 
viscosity, and DT is the translational diffusion coefficient. The particle size was derived 
using the Stokes-Einstein equation and the autocorrelation function using a non-negatively 
constrained least squares (NNLS) deconvolution algorithm.
EAE Model
The 6–8 week old female SJL/J mice for the Route of Administration study were purchased 
from Charles River Laboratories, Inc. (Wilmington, MA). The 3-week old female SJL/J 
mice for the dosing study were purchased from Harlan Laboratories, Inc. (Indianapolis, IN). 
The mice were housed in a pathogen-free facility at the University of Kansas approved by 
the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). 
All experimental procedures using live animals have been reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) at the University of Kansas.
On Day 0 of the study, the SJL/J mice were induced with EAE through four 50-μL injections 
of an emulsion containing Incomplete Freund’s Adjuvant Oil (BD Difco Adjuvants, 
Franklin Lakes, NJ), Mycobacterium tuberculosis (BD Difco Adjuvants, Franklin Lakes, 
NJ), and 200 nMol of PLP per animal. The SC injections were given above each of the 
shoulder blades and the rear haunches of the mouse. Each animal was also given a 100-μL 
IP injection of 200 ng of pertussis toxin (List Biological Laboratories, Inc., Campbell, CA) 
on Days 0 and 2. The mice were weighed on each day of the 25-day study and were given a 
clinical score ranging between 0 and 5 from Day 7 to the end of the study. The clinical score 
increases with disease progression. Scores increased in correlation with the level of 
paralysis, starting with the tail and advancing to the head. The following clinical score scale 
was used: 0 – no symptoms of disease were seen, 1 – limp tail and waddling gait, 2 – partial 
hind leg paralysis, 3 – paraplegia (complete hind leg paralysis), 4 – partial front leg 
paralysis, 5 – moribund or complete front leg paralysis. The mice were then treated on Days 
4, 7, and 10 with 100 μL of SAgA (containing 200 nMol of PLP) on each treatment day, 
unless otherwise stated. There were 6 mice in each group, with three mice housed together 
per cage. All the statistical analysis was done on Prism GraphPad 5 software, using ANOVA 
analysis.
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Changing the Dose Schedule, Volume, and Amount of SAgA Treatment
EAE mice were treated on only one of the three days mentioned (day 4, 7, or 10). Days 4 
and 7 was chosen as a treatment day to monitor disease progression if treatment occurred 
prior to symptoms and day 10 was chosen to track the disease severity if treated after the 
symptoms were visible. SAgA was still given on a 200-nMol PLP basis using 100 uL per 
injection. Two other variables were changed in the study, the amount of SAgA given and the 
volume of the injection. One group of mice was treated on a 50-nMol PLP basis of SAgA 
(100 uL per injection) given on all three treatment days. Another group of mice was treated 
on a 200-nMol PLP basis of SAgA using 20 uL per injection given on all three treatment 
days. All of these injections were given in the Upper SC site. The same SAgA was used for 
each animal study and the PLP:LABL ratio (1:1) was kept the same in each study.
As a negative control, a group that only received phosphate buffered saline (PBS) as a 
treatment was included in each study. A group that received a SC SAgA injection in the 
upper back was also included as a positive control in each study since treatment route was 
used in previous12,15.
Route of Administration EAE Study
The administration routes initially explored were IM, SC, and IP. More sites were then 
added to test whether clinical scores may improve if administering SAgAs near the upper 
lymph nodes, close to the spinal cord. As a result, the following injection sites were used: 
IP, Upper IM, Lower IM, Upper SC, and Lower SC (Figure 1).
In a second component of the study, IV and pulmonary routes were also compared to the 
Upper SC delivery of SAgAs. A tail vein IV injection site was chosen to measure what the 
effect systemic delivery of SAgA would produce. SAgAs were given at a 200-nMol PLP 
basis at an injection volume of 100 μL. For PI, SAgAs were given at a 200 nMol PLP basis, 
but the injection volume was decreased to 50 μL due to the limitation in volume that can be 
safely delivered to lungs. Administration positive and negative controls were included for 
both studies as mentioned above.
For PI administration, each animal was anesthetized with inhaled isoflurane in an induction 
chamber. After the mouse was fully anesthetized, the mouse was positioned with its back on 
a dosing board at approximately a 60° angle to a supine position using a thin wire to suspend 
them by their incisor teeth with a nose cone being used to maintain anesthesia. The mouth 
was opened and the tongue was gently pulled out and to the side of the mouth. A 
laryngoscope was then positioned to depress the tongue and see the cords at the top of the 
trachea and 50 uL of solution was administered at the top of the trachea. The tongue was 
withheld for 3 breaths at which time the mouse was maintained under anesthesia for an 
additional 3 minutes on the dosing board. The mouse was then removed from the dosing 
board and held vertically until she began to recover from the anesthesia.
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Before any of the SAgAs were injected into animals, the amount of peptide per SAgA was 
confirmed. For the first EAE study exploring the dosing schedule, amount and volume, 
approximately 9 LABL molecules and 8 PLP molecules were in SAgAs. Table 1 reports the 
characteristics of SAgAs that were used for the remaining two routes of administration 
studies. Using these data, a 200-nMol PLP dose was calculated for each SAgA treatment. 
The average molecular weight of the SAgA, the approximate number of PLP and LABL 
molecules on one 16 kDa HA chain, and the final ratio of PLP:LABL in SAgA were 
calculated using reverse phase HPLC data. (Table 1)
DLS
Figure 1 shows the hydrodynamic radius of SAgAs ranged between 3 – 10 nm. At 
concentrations at 1 mg/mL and lower, SAgA size ranged between 5 – 10 nm. SAgAs were 
injected at a maximum of 10 mg/mL, which falls in the size range of 3 – 10 nm. A range of 
sizes was expected for SAgAs since the starting HA exhibits a size distribution and the 
number of peptides associated with each HA strand may vary. According to studies tracking 
passive tissue drainage of HA, SAgAs at the higher end of the size distribution (~10 nm) 
would be expected to infiltrate the lymphatic system. At the lower size range (~3–5 nm), 
SAgAs would be more likely to enter the systemic circulation. The size of SAgAs is also 
small enough to bind immune cells and be actively transported to secondary lymphoid 
organs.
EAE Study of Dosing Schedule, Amount, and Volume
The SAgA dosing schedule has been determined from work by Siahaan et al. using their 
bifunctional peptide inhibitor (BPI), which is a small molecule version of SAgAs that 
contains PLP and LABL with a linker in between. BPI ameliorated disease best when given 
on days 4, 7, and 10, at a concentration of 100 nMol16–19. In early studies, SAgAs were 
injected on a 100-nMol PLP basis, but after a small dosing study, it was found that a 200-
nMol PLP basis decreased clinical scores of EAE mice more than the 100-nMol dose12,15.
Here, the treatment schedule was changed to a single SC injection on only one of the three 
treatment days (day 4, 7, or 10 of the study). Treating only on day 7 seemed to decrease the 
disease symptoms the most when compared to either the PBS-treated group or the group that 
received treatment on all three days. Differences in clinical score, however, were not 
significantly different (Figure 2A). The incidence of disease graph is another way to view 
the clinical scoring of animals. A score of 1.5 indicates that the animal experiences full 
paralysis of the tail with partial paralysis of hind-limbs. As a result, 1.5 is a critical score to 
determine if the disease affects mouse movement or not. The incidence of disease for 
variation of dosing schedule (Figure 2B) indicated, however, that only half of the group 
dosed on day 7 had a score of 1.5 or higher.
In another study, the dose was decreased from 200 nMol PLP to 50 nMol PLP. As 
mentioned above, the SAgA dose was calculated based on the amount of conjugated PLP 
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antigen administered. Decreasing the dose reduced efficacy, even if the SC treatment was 
dosed on all three days. The clinical scores (Figure 2C) and incidence of disease (Figure 2D) 
resembled that of the PBS control group more closely than the group that was treated at the 
200-nMol dose on all three days.
Lastly, the total volume of the SC injection was reduced from 100 μL to 20 μL, while 
maintaining the 200-nMol PLP dose. The clinical score data (Figure 2E) showed no 
difference compared to either of the control groups (PBS or SAgA treatment using 100 μL 
injections). The incidence of disease (Figure 2F), however, suggested lowering the injection 
volume reduced efficacy in a majority of the animals, even when the dose injected did not 
change. The significant difference in clinical scores between the 20 μL and the 100 μL 
injection suggested a larger injection volume may improve SAgA exposure (e.g. local 
drainage or systemic absorption).
EAE Study of Routes of Administration
Next, the 200-nMol dose in 100 μL was injected into different sires: upper SC (as before), 
lower SC, upper IM, lower IM, and IP (Figure 3). In exploring the different routes of 
administration, each of the treatments was found to be statistically significant (p<0.05) from 
the PBS control group during the peak of disease, days 12–17 (Figure 4A). In this study, no 
difference was apparent between different SAgA routes of administration. Both the clinical 
score data and the weights of the animals revealed differences between the PBS control 
group and the various treatment groups. The incidence of disease graph (Figure 4B), 
however, suggested the upper IM group had the lowest number of animals with a disease 
score of 1 or higher.
A subsequent study compared upper SC, IV, and PI routes of administration. The SC and IV 
group scores (Figure 4C) and weights (Supplemental Figure 2E) were similar to one another 
and were, once again, significantly improved compared to the PBS group (p<0.05) during 
the peak of disease. The PI group maintained a clinical score of zero and showed the best 
maintenance of weight throughout the study. In the incidence of disease profiles (Figure 
4D), no mice in the PI group had a clinical score of one or higher, further supporting 
pulmonary instillation of SAgAs provided the best amelioration of disease.
DISCUSSION
In vaccine treatments, IM injections are usually given to produce an immune response. In 
contrast, SC injections are typically used for hyposensitization of patients (e.g. allergy 
shots). Subcutaneous injections are more likely to diffuse from the injection site, where as 
intramuscular injections may form a depot, depending on the properties of the injected 
material. Since transport to the lymph nodes was thought to be vital for SAgAs, the SC route 
was chosen as it allows for both active transport and passive diffusion to the lymph nodes. 
Bagby et al. have found that injecting HA subcutaneously in a mouse footpad results in HA 
draining to lymph nodes14. Since SAgAs contain HA and are delivered subcutaneously, it is 
possible that they can also be transported to the lymph nodes, either by passively draining 
with interstitial fluid or by active transport by binding immune cells. Additionally, SC 
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injection of SAgA was previously shown to decrease EAE scores, so dose schedule, amount, 
and volume were explored by this route first12,15.
EAE Study of Dosing Schedule, Amount, and Volume
Treating on one of the three treatment days or injecting SAgA at a lower concentration 
generally caused the disease symptoms to increase compared to treating on days 4, 7, and 10 
with 200 nMol PLP conjugated to SAgA. Treatment on day 4 did not allow for the disease 
to fully manifest, since 7 – 10 days are required for the immune response to occur20. 
Treatment on day 10 allowed for the symptoms to be apparent, which means that the 
immune system has already damaged the CNS (e.g., spinal cord). The incidence of disease 
graph having clinical score greater than 1.5 supports the argument that day 7 had the lowest 
incidence of disease, however clinical scores were similar for all days.
Arguably, day 10 would be the most similar to a clinical setting with a human subject. While 
considering the incidence of disease trends, administering treatment after symptoms have 
persisted for a few days seems not as effective as treating earlier. For full effectiveness, it 
may be important to treat before the symptoms are felt, with enough time for the body to 
process an immunological response. For example, natalizumab treatment regimen is given 
on a monthly schedule, prior to symptom presentation, which would be similar to early 
treatment using SAgA21–24. These similar mechanisms suggest SAgAs may be interacting 
with immune cells and somehow inhibiting trafficking, sequestering these cells in lymphoid 
tissue, or triggering anergy.
SAgAs were not as effective when the overall dose was decreased from 200 nMol to 50 
nMol PLP. All six of the mice had a clinical score greater than 1.5 just one day after the 
PBS-treated group reached that level. While the onset of disease was slightly delayed, 
symptoms progressed very quickly once present. Going forward, a 200-nMol PLP dose was 
deemed necessary for SC delivery to be effective.
To test the last dosing variable, SAgA concentration was increased to deliver 200 nMol of 
PLP in 20 μL instead of 100 μL. The injected material was hypothesized to remain more 
local and not spread under the skin to the same extent as in the typical 100 μL injection 
groups. While the onset of disease was delayed, the majority of the animals did get sick. The 
smaller volume injected did decrease the clinical score, but it was not as effective as the 
larger volume injection even though the dose was the same. In conclusion, the 100 μL SC 
injection of SAgA allowed for better amelioration of disease perhaps because of improved 
local distribution and exposure, compared to the lower volume injection. The larger volume 
injection was observed to spread under the skin to a greater extent than the smaller volume 
injection. As a result, the injection is much more likely to spread itself over a large surface 
area, giving SAgAs an increased likelihood of absorption or binding to peripheral immune 
cells for active transport. It is reasonable to suspect the higher volume injection may have 
even hydrostatically perfused more SAgA into lymphatic ducts, since lymph node clearance 
is driven by a pressure differential between the lymphatic ducts and tissue space.
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EAE Study of Route of Administration
Since changes in dose and injection volume changed response, the route of administration 
was hypothesized to have an important effect. EAE mice were treated using the most 
effective regimen (200 nMol PLP, 100 μL injection days 4, 7, 10) by injecting upper SC, 
lower SC, upper IM, lower IM, or IP. All of the routes of administration significantly 
improved the disease state compared to the PBS group, but the treatment groups did not 
differ from each other (Figure 4A). Comparing the severity of disease in individual animals 
showed no animals in the upper IM group had a disease score of 1.5 or higher, whereas 5 out 
of 6 animals in the upper SC group had a score of 1.5 or higher at the peak of disease 
(Figure 4B). Additionally, all of the mice in the PBS control group had a score of 1.5 or 
higher by day 13.
SAgAs were originally designed to transport to the lymph nodes, through either passive 
drainage or active transport. Passive drainage allows SAgAs to diffuse with interstitial fluid 
to the lymph vessels, then drain to the appropriate lymph nodes. During active transport, 
peripheral antigen presenting cells such as macrophages or dendritic cells may carry SAgAs 
to the lymph nodes (e.g., after recognizing PLP antigen25). Intravenous delivery of SAgAs 
was used to compare results from upper and lower SC, upper and lower IM, and IP 
injections. Similar efficacy via different routes of administration chosen for this study would 
suggest SAgAs may act systemically to ameliorate EAE. This is supported by DLS data that 
indicates the size distribution of SAgAs would include some SAgA molecules that may be 
small enough to enter the circulation and some SAgA molecules large enough to favor 
passive drainage via the lymph vessels.
IV administration using the same SAgA dose injection volume and schedule was compared 
to upper SC administration. The IV route provided similar disease amelioration and this 
group provided a key benchmark for comparing other routes of administration (Figure 4C). 
Since there was no difference in scores between the IV and the SC groups, it is probable that 
the SC injection is also delivering SAgAs systemically. Small, twenty-gram mice were 
injected with 100 μL, perhaps increasing the likelihood that SAgAs absorb into circulation 
instead of creating a depot. In the incidence of disease graph (Figure 4D), the SC and IV 
treatment groups both had over half of the mice that were affected by the disease. This 
complements the clinical score data for the SC and IV treatment groups, supporting the 
notion that subcutaneous injection may lead to systemic delivery of SAgA. SAgAs may 
transport to the spleen when delivered systemically, which may allow for the SAgAs to 
interact with B and T cells. Further studies would be needed to support or disprove this 
hypothesis.
Finally, another route of administration was explored in this study, pulmonary instillation. In 
the ‘Hub and Spoke’ model of the immune system, T cells are licensed in the lung before 
they are distributed throughout the body2. In the case of multiple sclerosis, the lung is the 
hub and the CNS tissue is the spoke. Odoardi et al also determined that T cells acquire the 
properties needed to migrate to other parts of the body in the lung1. Delivering SAgAs to the 
lungs may allow multiple sclerosis-specific T cells to interact with SAgAs. An exact 
mechanism between T cells and SAgAs is still being explored, but delivering SAgAs to the 
lungs proved to significantly decrease EAE disease symptoms. After PI of SAgAs, mice 
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showed disease scores of zero throughout the course of the 25-day study. In comparison to 
other routes of delivery (e.g., SC and IV), pulmonary delivery provided the lowest clinical 
scores, the best maintenance of weight, and no animals were affected by disease (Figures 4C 
and 4D).
The increased efficacy of PI of SAgAs compared to subcutaneous or intravenous injection 
may also be explained by some of the physiological differences in transport. Several 
different transport processes may occur after PI. Passive transport routes include diffusion of 
SAgAs through the lung epithelial tissue, followed by absorption into the lymphatic network 
or into circulation. Xie et al, determined that pulmonary instillation of an HA conjugate 
allowed the majority of the drug to stay within the lung, where it could be targeting the 
surrounding lymph nodes26. It is possible that the effect of SAgAs after PI administration is 
more pronounced than SC or IM because of the shorter pathways from the lung to the lymph 
node, thus leading to higher dose or better timing during the pre-symptomatic stage of 
immune response.
Another possibility to consider is that SAgA degradation and diffusion of components is 
possible, but our previous studies have shown neither free peptides nor HA (alone or in 
combination) have a therapeutic effect12. Active processes of mucocillary clearance and 
macrophage clearance may also affect SAgA transport. Mucous is transported by cilia 
located in the conducting airways and is deposited in the oropharynx and swallowed. The 
potency of SAgAs administered PI suggest minimal mucociliary clearance. Macrophage 
clearance typically occurs in the lower airways including terminal bronchioles and alveoli. 
Macrophages then transport phagocytosed cargo to the lymph nodes for processing. Lymph 
nodes are key to the efficacy of immune therapies, since that is a primary site of immune 
cell priming.
Observations from SC and IV routes of administration do not support a systemic mechanism 
of SAgA efficacy of after PI. Although, it is possible increased PI efficacy is linked to 
avoiding fist pass metabolism, which could diminish SAgA effect after IV or SC 
administration. Furthermore, it is plausible the lung may act as a SAgA depot after PI, since 
macrophage clearance can take days, providing an extended duration of action compared to 
the other administration routes. Perhaps the most plausible explanation is that pulmonary 
instillation may offer a direct avenue to the lymphatic system, either passively or via active 
transport or may somehow bind and inhibit T cells migrating through the lungs to be 
licensed for trafficking to the CNS. Additional studies will be required to elucidate these 
possible mechanisms.
CONCLUSION
SAgA treatment schedule, dose, injection volume, and routes of administration were 
systemically explored to treat EAE. Timing the SAgAs dose was important, suggesting it 
must follow the schedule of a typical natalizumab dosing, before symptoms are fully 
realized. Decreasing SAgA dose to 50 nMol (i.e. 50 nMol of PLP delivered) administered on 
days 4, 7, 10 was not as effective as 200 nMol. Decreasing the volume of the dose to 20 μL 
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meant increasing the concentration 5 fold and SAgAs were slightly less efficacious at the 
lower volume, suggesting the lower volume, higher concentration had limited exposure.
Exploring routes of administration provided new insight into possible mechanisms of action. 
The initial goal was to deliver SAgAs to lymph nodes. The first set of administration sites 
(upper and lower SC, upper and lower IM, and IP) was chosen with this goal in mind. 
Previous studies suggested a portion of SAgAs injected at the upper SC site would drain to 
the cervical lymph nodes, which drain the CNS and are implicated in EAE. Delivering 
SAgAs via the SC route was similar to delivering IV suggesting all peripheral injections 
may be acting via systemic exposure. The most surprising result was that the pulmonary 
delivery of SAgAs decreased the clinical scores with no mice exhibiting symptoms 
throughout the study. Applying the ‘Hub and Spoke’ theory to pulmonary delivery, it is 
possible that delivering SAgAs to the lungs allows maximized interaction with the immune 
system, either within the lung or via local lymphatics.
To further explore mechanisms of SAgA efficacy, the dosing schedule, amount, and volume 
studies could be repeated via the pulmonary instillation route of administration. Further 
studies that track the distribution of SAgA throughout the mouse after pulmonary instillation 
would provide useful insight to the trafficking of SAgA molecules. Additionally, in vitro 
work is under way to determine target cells by screening SAgAs in EAE splenocytes and 
measuring cytokine responses to help explain the efficacy observed in EAE mice.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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DLS measurements show various concentrations of SAgAs to measure between 3 – 10 nm 
in hydrodynamic radius.
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Clinical score and incidence of disease data for dosing schedule, dosing amount and dosing 
volume. For the incidence of disease data, a disease score of 1.5 or higher shows that the 
animal is affected by the disease. (A) Dosing schedule was changed to one of the three 
treatment days. There is significance (p<0.05) on Days 13 and 15 of the study between the 
PBS control group and the group that was treated only on Day 7. (B) The incidence of 
disease for the dosing schedule study shows that treating on Day 7 results in the lowest 
incidence of disease. (C) Dosing amount clinical scores indicated that decreasing the dose 
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decreases the effectiveness of the treatment. (D) The incidence of disease for the dosing 
amount study showed that decreasing the dose increased the number of animals affected by 
the disease. (E) The dosing volume clinical scores showed that the lower volume injection is 
not as effective in comparison to the 100 uL injection. (F) The incidence of disease for 
dosing volume shows that the lower injection volume had a 50% greater incidence of 
disease.
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Injection sites for route of administration studies.
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Route of administration study clinical score (A) and incidence of disease (B) data. (A) There 
is no difference between different routes of administration, but there is a significant 
difference (p<0.05) between the PBS-treated group and all other SAgA-treated groups on 
Days 12–18. (B) Incidence of disease plots show animals with a disease score of at least 1.5 
affected by the disease. The upper IM group was the least affected and the PBS-treated and 
upper SC groups were the most affected. (C) The pulmonary instillation group had disease 
scores of 0 throughout the peak of disease. (D) No animals in the pulmonary instillation 
group had a score of 1.5 or higher.
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Table 1
Using pH 1.0 solution, the peptides were hydrolyzed from HA to indirectly quantify the amount of AoPLP 











39605 8.84 8.27 1.069:1
34269 6.42 6.85 0.94:1
34788 8.19 5.53 1.48:1
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